KR101472190B1 - Composition for preventing, treating or improving constipation comprising plant originated tyndalized lactic acid bacteria, Lactobacillus plantarum PMO08 dead cell as an active ingredient - Google Patents

Abstract

More particularly, the present invention relates to a novel use of Lactobacillus plantarum pmi 08 bacteria cells, and more particularly to a novel Lactobacillus plantarum pumio 08 cellulase or Lactobacillus plantarum pumio 08 cellulase, And a composition for prevention and treatment / improvement of constipation comprising the mixture as an active ingredient. The mixture of Lactobacillus plantarum pomo 08 strain of the present invention or Lactobacillus plantarum pim01 08 and the mixture of aloeferrox effectively promotes intestinal feeding ability, regulates moisture absorption and intestinal absorption, Prevention and treatment / improvement. Therefore, the microbial cells of the present invention can be used for the purpose of prevention, treatment and improvement of constipation.
[Index]
Lactobacillus plantarum pemoi 08 dead cells, aloe perox, constipation

Description

[0001] The present invention relates to a composition for preventing, treating or improving constipation comprising, as an active ingredient, bacterial cells of Lactobacillus plantarum Lactobacillus plantarum pimae 08. [0002] The present invention relates to a composition for prevention, treatment or improvement of constipation comprising plant cells of Lactobacillus plantarum PMO08 dead cell as an active ingredient}

The present invention relates to a novel use of a plant lactic acid bacterium Lactobacillus plantarum pmi 08 cell, and more specifically, to a novel use of a plant lactic acid bacterium Lactobacillus plantarum pumio 08 cellulase or a lactobacillus plantarum pumbao 08 Compositions for prevention and treatment / improvement of constipation comprising a mixture of microorganism cells and aloeferox as an active ingredient.

Lactic acid bacteria, which are abundant in fermented foods, play a role in decomposing fibrous and complex proteins into important nutritional components in a symbiotic relationship with the digestive system of the human body. Thus, the intestinal microbial environment of the host is improved in the gastrointestinal tract of animals including humans Living microorganisms that have a beneficial effect on the health of the host are collectively referred to as probiotics.

Lactic acid bacteria are lactic acid bacteria that produce carbohydrates and make lactic acid by using them. They are tuberous anaerobes or organisms that grow well in low oxygen. Lactic acid bacteria can be divided into five genus, Streptococcus, Lactobacillus, Leuconostoc, Bifidobacteria and Pediococcus.

The streptococcus microorganism, a streptococcus strain, is a homozygous fermenting microorganism. It is known to inhibit spoilage bacteria and pathogens by fermenting milk to produce lactic acid. Lactobacillus microorganisms are homozygous or heterozygous fermenting lactic acid bacterium, which are common bacteria in the fermentation process of dairy products and vegetables. The microorganisms of the genus Lucococcus are heterozygous and mainly involved in the fermentation of vegetables. Bifidobacterial microorganisms are organisms that do not grow in the presence of oxygen, and fermentation of sugars produces L (+) -like lactic acid, which can be metabolized to infants. Finally, the microorganism of Pediococcus is a homozygous fermenting microorganism in the form of sycamore, which is present in kimchi or pickled food and is involved in the fermentation of meat such as sausage.

Among them, microorganisms of the genus Lactobacillus are lactic acid bacterium that is homozygous or heterozygous fermenting, and are commonly found in the fermentation process of intestines, dairy products and vegetables of animals including humans. Lactobacillus microorganisms maintain intestinal pH acidic and inhibit the growth of harmful microorganisms such as E. coli and Clostridium, and improve diarrhea and constipation, as well as vitamin synthesis, anti-cancer effects, serum cholesterol lowering And so on. Acidophilin produced by lactic acid bacterium is known to inhibit the growth of Alzheimer, Salmonella, Staphylococcus, and Escherichia coli. It inhibits the growth of diarrheal pathogens and normalizes intestinal microflora to stop diarrhea.

Recently, the function of Lactobacillus plantarum isolated from plants such as vegetables and fruits, or foods fermented with fruit and vegetables such as kimchi has been revealed and emerged as a new functional material. Acid resistance, bile resistance and antibiotic resistance effect of Lactobacillus plantarum Jay 124 (Korean Patent Application No. 2002-0049220), Listeria monocytogenes of Lactobacillus plantarum jay 9 (Korean patent application No. 2003-0067073) And Enterococcus faecalis , Lactobacillus plantarum CJ Lipi 243 (Korean Patent Application No. 2009-0102822), intestinal disease treatment and immunity enhancing effect, Lactobacillus plantarum W. W. 7711 2009-0058180) have been disclosed to have antioxidant and anti-inflammatory efficacy. Lactobacillus plantarum pmi 08 (Korean Patent Application No. 2009-0130699), which has anticancer or antimicrobial activity most recently, has been disclosed.

However, the above results have confirmed the physiological activity of the lactic acid bacteria. There is a limitation in considering the method for enhancing the inherent functions of the lactic acid bacteria.

Accordingly, the inventors of the present invention have been studying the function of Lactobacillus plantarum pimio 08 (KFCC-11028), which is a kind of plant lactic acid bacteria, and found that when Lactobacillus plantarum pimio 08 (KFCC-11028) The present invention has been completed based on the discovery that there is an effect of preventing and treating constipation in a complex with aloe ferox plant.

Accordingly, an object of the present invention is to provide a novel use of a mixture of Lactobacillus plantarum pimio 08 (KFCC-11028) cells or Lactobacillus plantarum pimonidium 08 cells and an aloeferox mixture.

In order to achieve the object of the present invention, the present invention provides a composition for preventing and treating constipation, which comprises a mixture of Lactobacillus plantarum pmi 08 (KFCC-11028) and a plant mixture of aloeferox A pharmaceutical composition is provided.

In order to accomplish another object of the present invention, the present invention provides a composition for preventing and improving constipation, which comprises a mixture of Lactobacillus plantarum pmi 08 (KFCC-11028) dead cells and an aloeferox plant as an active ingredient To provide a food composition.

In order to accomplish still another object of the present invention, the present invention provides a pharmaceutical composition for preventing and treating constipation characterized by containing cells of Lactobacillus plantarum pmi 08 (KFCC-11028) as an active ingredient .

In order to accomplish still another object of the present invention, there is provided a food composition for preventing and improving constipation, which comprises Lactobacillus plantarum pmi 08 (KFCC-11028) dead cells as an active ingredient.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for preventing and treating constipation, which comprises a mixture of Lactobacillus plantarum pimero 08 (KFCC-11028) dead cells and an aloe perox plant as an active ingredient.

In one embodiment of the present invention, the ability to deliver intestinal fluids to the rofeelamide treated group was confirmed. As a result, it was confirmed that the lactic acid bacterium of the present invention increased the intestine feeding ability as compared to the ropelemide alone treatment group, which is superior to the live bacteria. Particularly, the mixture of lactic acid bacterium cells and aloeferox was shown to have a near-to-normal range of movement, indicating excellent constipation-improving effects (see Example <1-2>).

In another embodiment of the present invention, the number of feces, the weight of the feces, and the moisture content of the feces were measured as biomarkers in order to measure the constipation-improving effect according to the ingestion of the experimental material. As a result, it was confirmed that the inventive lactic acid bacterium cells or the lactic acid bacterium cells of the present invention and the aloeferox mixture increased the number of mites and the weight of varieties, and particularly maintained the water content of the feces at a normal level, (See Example <2-2>). The intestinal tissues were also excised and the amount of fecal matter remaining in the intestines was confirmed. As a result, it can be seen that the lactic acid bacterium cells of the present invention or the lactic acid bacterium cells of the present invention and the aloeferox mixture have a smaller amount of feces remaining in the intestines as compared with the control group. In particular, the lactic acid bacterium cells of the present invention and the aloeferox mixture It was found that the most excellent effect was obtained (see Example <2-3>).

Therefore, in the present invention, it has been confirmed that Lactobacillus plantarum pimio 08 (KFCC-11028), which is a kind of vegetable lactic acid bacteria, has excellent effects on improving constipation, and a composition for preventing and treating constipation to provide. In particular, the composition of the present invention may contain a mixture of Lactobacillus plantarum pimio 08 (KFCC-11028) cells and an aloeferox mixture as an active ingredient. The mixture of aloe ferox was able to reduce the dose of lactic acid bacterium significantly, and with a smaller number of dead bacterium (about 1/2 in the experiment), a more effective effect was obtained. In particular, there was a beneficial effect in that synergistic effect was observed in the intestinal water reabsorption-regulating function, which is superior to the ingestion of dead cells alone.

The aloe is a raw material having a scientific name Aloe ferox Miller as presented in the Food Code and does not include the shell of aloe leaf juice. In addition, hot water or alcohol extract (or its concentrate, extracted powder thereof) of Aloeferox plant with respect to the active ingredient, enzyme treated product, juice, and crushed product through enzyme treatment can be used.

Meanwhile, the composition of the present invention may be a pharmaceutical composition or a food composition.

The pharmaceutical composition according to the present invention comprises a pharmacologically effective amount of a lactobacillus plantarum pmi 08 saccharide or a mixture of lactobacillus plantarum pmi 08 saccharide and an aloeferose mixture alone or in combination with one or more pharmaceutically Additional acceptable carriers may be included. The pharmaceutical compositions of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol in which multiple doses are administered over a prolonged period of time. The term "pharmaceutically effective amount" as used herein refers to an amount that exhibits a reaction higher than that of the negative control, and preferably refers to an amount sufficient to treat or prevent constipation. The effective amount of the Lactobacillus plantarum pomo 08 strain or the lactobacillus plantarum pimozo 08 strain and the aloeferrox mixture according to the present invention is 0.001 to 1000 mg / day / kg body weight, but is not limited thereto . However, the pharmaceutically effective amount may be appropriately changed depending on various factors such as the disease and its severity, the patient's age, body weight, health condition, sex, administration route and treatment period.

The composition of the present invention can be variously formulated according to the route of administration by a method known in the art together with the pharmaceutically acceptable carrier. The term "pharmaceutically acceptable" as used herein means a non-toxic composition which is physiologically acceptable and which, when administered to humans, does not inhibit the action of the active ingredient and does not normally cause an allergic reaction such as gastrointestinal disorder, dizziness, . The composition of the present invention can be variously formulated according to the route of administration by a method known in the art together with the pharmaceutically acceptable carrier. Routes of administration include, but are not limited to, oral or parenteral administration.

When the pharmaceutical composition of the present invention is orally administered, the pharmaceutical composition of the present invention may be formulated into a powder, a granule, a tablet, a pill, a sugar, a tablet, a capsule, a liquid, a gel , Syrups, suspensions, wafers, and the like. Examples of suitable carriers include saccharides including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, Cellulose such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose and the like, fillers such as gelatin, polyvinylpyrrolidone and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may optionally be added as a disintegrant. Further, the pharmaceutical composition may further comprise an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent.

In addition, when parenterally administered, the pharmaceutical composition of the present invention can be formulated according to a method known in the art together with a suitable parenteral carrier.

Other pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences, 19th ed., 1995, Mack Publishing Company, Easton, PA).

Furthermore, the pharmaceutical composition of the present invention can be administered in combination with a known compound having an effect of preventing and treating constipation.

In addition, the Lactobacillus plantarum pneumococcus 08 strain or Lactobacillus plantarum pneumatic 08 cells and the aloeferrox mixture according to the present invention may be provided in the form of a food composition for the purpose of preventing and / or improving constipation . The food composition of the present invention includes all forms of functional food, nutritional supplement, health food and food additives, lactic acid bacteria drink, fermented milk, green juice and the like. Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art.

For example, as the health food, the Lactobacillus plantarum pomo 08 strain of the present invention or the Lactobacillus plantarum pomo 08 strain of the present invention and the aloeferrox mixture itself can be used as a green juice, a lactic acid bacterium, a fermented milk, a tea, It can be made in the form of a drink and taken for drinking, granulated, tabletted, encapsulated and powdered. In addition, the lactobacillus plantarum pomo 08 strain of the present invention or the lactobacillus plantarum pimero 08 strain and the aloe feroxic acid mixture may be mixed together with a known substance or active ingredient known to have the effect of improving constipation, . &Lt; / RTI &gt;

Functional foods also include beverages (including alcoholic beverages), fruits and their processed foods (such as canned fruits, bottled, jam, marmalade, etc.), fish, meat and processed foods such as ham, sausage, Breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), juice, various drinks, cookies, sugar, dairy products such as butter, cheese, edible vegetable oil, vegetable protein, retort food, , Lactobacillus plantarum pMM0 08 cells or Lactobacillus plantarum pMM0 08 cells and aloeferox mixture of the present invention can be added to various kinds of seasonings (for example, soybean paste, soy sauce, sauce, etc.) .

The preferred content of the Lactobacillus plantarum pomo 08 cells or the mixture of Lactobacillus plantarum pomo 08 cells and the aloeferox mixture in the food composition of the present invention is not particularly limited, &Lt; / RTI &gt;

In addition, in order to use the lactobacillus plantarum pomo 08 strain of the present invention or the mixture of lactobacillus plantarum pimero 08 cells and the aloeferox mixture in the form of a food additive, they may be used in the form of a powder or a concentrate .

As described above, the mixture of Lactobacillus plantarum pumayeo 08 cells or Lactobacillus plantarum pimae 08 cells of the present invention and aloeferox mixture not only promotes the ability of the intestines to be transported, It is effective in preventing constipation and treating / improving constipation. Therefore, the lactic acid bacterium cells of the present invention can be used for the purpose of preventing, treating and improving constipation.

Figure 1 shows the feeding capacity of each experimental group.
Fig. 2 shows the amount of feces remaining in the colon by each experimental group.

Hereinafter, the present invention will be described in detail by way of examples.

However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

&Lt; Example 1 &gt;

Evaluation of intestinal feeding ability

<1-1> Setting and processing of experiment group

As shown in Table 1 below, the experimental animals (ICR mice, 7 weeks old) were divided into five groups from G1 to G5 in the experimental group, and all the experimental groups were divided into two groups by the gut nutritional method: Lactobacillus live bacteria and dead bacteria alone or Lactobacillus / Was administered once daily for 7 days at the same dose per individual in the stomach and then on the 8th day after a fasting period and loperamide was administered subcutaneously.

Lactobacillus plantarum Lactobacillus planta PMO08 (1.0 × ^{10 11} cfu / g) produced by Probiotics health functional food probiotics was used in Cell Biotech Co., Ltd., And the bacterium was a plant lactobacillus Lactobacillus plantarum pumio 08 The raw materials produced by CELL BIOTECH CO., LTD., Manufactured by the following method, were used. The number of cells of this raw material was 1.0 × ^{10 11} cells / g, and was used in the same manner as the viable cell count.

<1-2> Measurement of feeding ability

The gastrointestinal transit test was conducted as follows to evaluate the effect of the empirical formula to improve constipation after administration. (Charcoal meal 0.3) mixed with 5% and 10% by weight of activated charcoal (Sigma, USA) and gum arabic (simga, USA) 60 minutes after the administration of rofemide in Example <1-1> ml was orally administered and sacrificed 30 minutes later to remove the gastrointestinal tract. The rate of movement of intestinal tract from the duodenum to the ileum was investigated by the activated carbon diet. The same experimental method is referred to as gastrointestinal transit. The feeding ability of each experimental group is shown in Fig.

G2, a group treated with rofemide alone, showed a 20% reduction in intestinal transmission, a 30% reduction compared to the normal, and a significant increase in intestinal transport in the germs was observed compared with that of the live bacteria. Could know. In addition, it was confirmed that the combination of lactic acid bacterium cells and aloeferox combination treatment group had higher activity than that alone (see Fig. 1).

&Lt; Example 2 &gt;

Constipation improvement efficacy

<2-1> Setting and processing of experiment group

Experimental animals (ICR mice, 7 weeks old) were divided into six groups from S1 to S6 in the experimental group, and the microbial cells of the lactic acid bacteria (KFCC-11028), aloeferox, And loperamide (3 mg / kg) was subcutaneously injected into all experimental groups except S1 for 3 days from the 12th day of the experiment.

In G5, the lactic acid bacteria complex represents the lactic acid bacterium (KFCC-11028) dead cells of the present invention and the aloeferox mixture (mixture of dead cells and aloeferox 1: 1), and the contents thereof are converted into the contents of lactic acid bacteria and aloeferox 0.25 g / body weight of lactic acid bacteria and 0.25 mg / body weight of aloe ferox.

The aloe ferox was removed from the skin of aloe ferox, and only the gel was taken, followed by lyophilization and pulverization. As a positive control, Dulcolaxs (Korea Boehringer Ingelheim), a commercial medicine for constipation treatment, was used.

<2-2> Measurement of the number of feces, the weight of feces, and the moisture content of feces

Feces were collected from the experimental rats of Example <2-1> for 24 hours after the administration of roperidide, and the moisture content in the feces count, weight, and feces was measured.

The results of the above experiment are shown in [Table 3]. The number of fecal samples in the group administered with rofferaemide (S2) was 60% of that in the normal group (S1). It was confirmed that the number of fecal matter (S3), aloeferox (S4), and fungus complex (S5) groups were similar to those of the normal group. On the other hand, the Dulcolax administration group (S6), which is a positive control group, showed an improved effect than the control group (S2), but the improvement effect was not so significant, and it was confirmed that the effect of the dead complex (S5) was more effective. In the fecal weight, the group (S2) administered only with looperamide was 65% level of the normal group (S1), and the fecal matter (S3) and dead mold compound (S5) And the removal effect was excellent. In addition, the moisture content in the feces was found to be effective in the order of the combination of the fungi (S5)> aloeferox (S4)> dead bacteria (S3)> positive control (S6) (S1), and it was confirmed that the effect of regulating moisture reabsorption in the intestines was excellent.

&Lt; 2-3 &gt; Measurement of residual amount of feces in large intestine

After the empirical formula was completed in Example <2-1>, the colon tissue was removed after fasting for 18 hours, and the number of the remaining feces in the large intestine was measured.

As a result, the number of fecal remains in the experimental group was 7.3 in the rope fermented group (S2), 5.0 in S3, 5.8 in S4, 4.7 in S5 and 6.3 in S6. The percentages of the remaining fecal samples for the G2 group were 100% for the ferulamide group S2, 100% for S2, 68% for S3, 79% for S4, 64% for S5 and 86% for S6 (See Fig. 2). It was confirmed that the number of feces remaining in the large intestine of the experimental group was smaller than that of the S2 group.

As described above, the mixture of the lactic acid bacteria Lactobacillus plantarum Lactobacillus flamarium lactic acid bacteria of the present invention or Lactobacillus plantarum pimonidium 08 cells and the aloeferox mixture effectively promotes intestinal feeding ability, And curettage elimination is effective in preventing and treating constipation / improvement. Therefore, the microorganism of the present invention can be used for the purpose of preventing, treating and improving constipation.

Claims (4)

A pharmaceutical composition for the prevention and treatment of constipation, which comprises a mixture of Lactobacillus plantarum pimero 08 (KFCC-11028) dead cells and aloeferox as an active ingredient. A food composition for preventing and improving constipation, which comprises as an active ingredient a mixture of Lactobacillus plantarum pimero 08 (KFCC-11028) dead cells and an aloeferox plant. A pharmaceutical composition for preventing and treating constipation, which comprises Lactobacillus plantarum pimero 08 (KFCC-11028) dead cells as an active ingredient. A food composition for preventing and improving constipation, which comprises Lactobacillus plantarum pimero 08 (KFCC-11028) dead cells as an active ingredient.

Images